Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Lymphoma, Non-Hodgkin × tafasitamab × Clear all

Phase

Status

Active not recruiting 2 Terminated 1 Recruiting 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 5 Lymphoma, B-Cell 3 Lymphoma 3 Lymphoma, Mantle-Cell 2 Recurrence 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Burkitt Lymphoma 1

Interventions

Cyclophosphamide 27 fludarabine 20 Rituximab 13 fludarabine phosphate 10 obinutuzumab 8 venetoclax 7 Lenalidomide 7 ibrutinib 6 Immunotherapy, Adoptive 6 Etoposide 6 pirtobrutinib 5 glofitamab 5 axicabtagene ciloleucel 5 Prednisone 5 polatuzumab vedotin 4 Specimen Handling 4 Doxorubicin 4 daratumumab 3 Whole-Body Irradiation 3 Vincristine 3 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3 Melphalan 3 Biopsy 3 tucatinib 2 tocilizumab 2 temsirolimus 2 relmacabtagene autoleucel 2 pomalidomide 2 pertuzumab 2 pembrolizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05583071 2025-08-13

MTR²

University of Cologne

Phase 2 Recruiting

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡